Landos Biopharma, Inc., incorporated in Delaware in January 2017, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of oral therapies for patients with autoimmune diseases. The company's core expertise is in the development of immune and metabolic therapy candidates for new pathways. Based on the understanding of the role of cellular metabolic pathways in regulating inflammatory responses, the company aims to inhibit these inflammatory responses by altering the metabolic processes of target cells. 

LABP(Delisted)